Skip to main content
Premium Trial:

Request an Annual Quote

DoubleTwist Licenses Prophecy Database to GPC Biotech

NEW YORK, Oct. 16 – DoubleTwist has licensed its Prophecy database and tools suite to GPC Biotech, the company said on Tuesday.

Financial terms of the agreement were not disclosed.

"DoubleTwist's Prophecy suite gives us comprehensive access to annotated public genome data and effective tools for their use,” Greg Hamm, vice president for bioinformatics at GPC Biotech said in a statement. “We are looking forward to mining this valuable data set.”

DoubleTwist, of Oakland, Calif., recently announced the release of its third-generation Prophecy database, which the company says includes an assembled genome of more than 35 databases onto a single genomic scaffold.

GPC Biotech, based in Munich, Germany, is a genomics- and proteomics-based drug-discovery company focused on drugs in oncology, infectious diseases, and immunology.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in EJHG find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.